1-3 of 3
Ramon V. Tiu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L. Tiv, Aine R. Knott, Margaret K. Wilkens, Kara M. Soroko, Mika Lin, Chiara Ambrogio, Monica Musteanu, Atsuko Ogino, Jihyun Choi, Magda Bahcall, Arrien A. Bertram, Emily S. Chambers, Cloud P. Paweletz, Shripad V. Bhagwat, Jason R. Manro, Ramon V. Tiu, Pasi A. Jänne
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 641–654.
https://doi.org/10.1158/1535-7163.MCT-20-0531
Published: 01 April 2021
View article titled, ERK Inhibitor LY3214996-Based Treatment Strategies for <em>RAS</em>-Driven Lung Cancer
Open the PDF for ERK Inhibitor LY3214996-Based Treatment Strategies for <em>RAS</em>-Driven Lung Cancer in another window
Journal Articles

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael J. Millward, Wei Zhang, Ling Gao, Amanda Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, KrisAnne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng-Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. Gordon, Ramon V. Tiu, David S. Hong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (2): 460–467.
https://doi.org/10.1158/1535-7163.MCT-19-0681
Published: 06 February 2020
View article titled, A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Open the PDF for A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Shripad V. Bhagwat, William T. McMillen, Shufen Cai, Baohui Zhao, Matthew Whitesell, Weihua Shen, Lisa Kindler, Robert S. Flack, Wenjuan Wu, Bryan Anderson, Yan Zhai, Xiu-Juan Yuan, Meghann Pogue, Robert D. Van Horn, Xi Rao, Denis McCann, Andrew J. Dropsey, Jason Manro, Jennie Walgren, Eunice Yuen, Michael J. Rodriguez, Gregory D. Plowman, Ramon V. Tiu, Sajan Joseph, Sheng-Bin Peng
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (2): 325–336.
https://doi.org/10.1158/1535-7163.MCT-19-0183
Published: 06 February 2020
View article titled, ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Open the PDF for ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine in another window
Includes: Supplementary data